 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...4748495051525354555657...235236» |
- Lutathera (lutetium Lu 177 dotatate) / Novartis
What Works for Ferret, Works for Man (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_286;
He was previously admitted for severe hypoglycemia and was treated with FOLFOX, LUTATHERA, Octreotide, TPN, steroids and diazoxide suspension...Changing the oral formulation to pill form allowed for better compliance, easy dose adjustments using insulin as a marker for response, and symptom resolution due to adequate suppression of insulin levels. Most importantly, it allowed for our patient to transfer out of the ICU and be discharged home with improved quality of life, a feat that was impossible without this change in formulation.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
IMPACT OF A NON-THERAPEUTIC LAPAROTOMY IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER UNDERGOING SURGICAL EXPLORATION TREATED WITH INDUCTION (M)FOLFIRINOX; A TAPS CONSORTIUM STUDY (Room S504, McCormick Place) - May 11, 2023 - Abstract #SSAT2023SSAT_449;
In total, 67 patients (10.1%) were included in group A, 425 patients (64.1%) in group B, and 171 patients (25.8%) in group C. Resection was aborted in 28.2% (n = 67/238) of all surgical explorations, commonly due to occult metastases (n = 30/238, 12.6%). The 90-day mortality in group A was 3.0% (n = 2/67).
- DISSECTING THE ROLE OF NODAL METASTASES LOCATION IN PANCREATODUODENECTOMY AFTER NEOADJUVANT TREATMENT FOR CANCER: RESULTS FROM A PROSPECTIVE LYMPHADENECTOMY PROTOCOL (Room S504, McCormick Place) - May 11, 2023 - Abstract #SSAT2023SSAT_447;
Examining second-echelon LNs does not improve the staging process substantially. Yet, second-echelon involvement is prognostically relevant, as well as metastases to station 8 and jejunal mesentery LNs.
- 5-fluorouracil / Generic mfg.
PATHOLOGIC COMPLETE RESPONSE FOLLOWING PREOPERATIVE CHEMORADIATION VS CHEMOTHERAPY FOR PANCREATIC DUCTAL ADENOCARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. (Room S505) - May 11, 2023 - Abstract #SSAT2023SSAT_386;
Among patients assigned to ChT the most frequent regimen was FOLFIRINOX (80%); among those who underwent CRT the most common regimen was FOLFIRINOX+RT (49.2%)...Conclusions. The use of CRT may have positive impact on pathologic response and R0 resection rate, whereas a benefit in survival was not reported, probably due to the risk of micrometastasis and distant metastasis that may impact on survival of locally advanced PDAC patients.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
AGGRESSIVE MANAGEMENT OF ELDERLY PATIENTS WITH NON-METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (Room S505) - May 11, 2023 - Abstract #SSAT2023SSAT_384;
However, they were just as likely to undergo surgical exploration and resection and had similar adjusted survival outcomes when compared to younger patients, highlighting the feasibility of aggressive management of PDAC in elderly patients, including the use of neoadjuvant FOLFIRINOX. . Kaplan-Meier curve depicting the overall survival outcomes for patients >=75 years old and <75years old with non-metastatic pancreatic adenocarcinoma who were initiated on neoadjuvant FOLFIRINOX therapy with curative-intent.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
PROGNOSTIC SIGNIFICANCE OF RESPONSE TO NEOADJUVANT FOLFIRINOX CHEMOTHERAPY AND EFFICACY OF ADJUVANT CHEMOTHERAPY ACCORDING TO RESPONSE TO NEOADJUVANT FOLFRINOX CHEMOTHERAPY (Room S505) - May 11, 2023 - Abstract #SSAT2023SSAT_377;
Completion of adjuvant chemotherapy is important in all patients regardless of response to neoadjuvant FOLFIRINOX chemotherapy, especially except for BR+/RR+, the efficacy was greater. Overall survival according to the biological and radiological response to neoadjuvant FOLFIRINOX Overall survival according to the completion of adjuvant chemotherapy A. Biochemical and radiologic responders B. Biochemical only responders C. Radiologic only responders D. Non-responders
- FAILURE TO ADJUVANT THERAPY AFTER PANCREATIC RESECTION FOR PANCREATIC CANCER (THE FOUNTAIN STUDY): A REAL-WORLD CONTEMPORARY ANALYSIS (Room S505) - May 11, 2023 - Abstract #SSAT2023SSAT_376;
P=N/A
Among such, Gemcitabine alone and FOLFIRINOX were employed in 42% and 38% of cases, respectively, followed by Gemcitabine-based(16%) and other regimes (5%). Main reasons for chemotherapy omission were postoperative failure-to-thrive (39%), baseline comorbidities (20%), and physician's decision (21%).
- DISSECTING THE ROLE OF NODAL METASTASES LOCATION IN PANCREATODUODENECTOMY AFTER NEOADJUVANT TREATMENT FOR CANCER: RESULTS FROM A PROSPECTIVE LYMPHADENECTOMY PROTOCOL (Room S504) - May 11, 2023 - Abstract #SSAT2023SSAT_275;
Results Among 288 patients 61% received FOLFIRINOX, 30% Gem-Abraxane...Moreover, intraoperative frozen section of station 8 might help decision-making, especially in technically demanding cases or fragile patients. Type of recurrence stratified by nodal parameters in node-positive patients
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
IMPACT OF A NON-THERAPEUTIC LAPAROTOMY IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER UNDERGOING SURGICAL EXPLORATION TREATED WITH INDUCTION (M)FOLFIRINOX; A TAPS CONSORTIUM STUDY (Room S504) - May 11, 2023 - Abstract #SSAT2023SSAT_274;
In total, 67 patients (10.1%) were included in group A, 425 patients (64.1%) in group B, and 171 patients (25.8%) in group C. Resection was aborted in 28.2% (n=67/238) of all surgical explorations, commonly due to occult metastases (n=30/238, 12.6%). The 90-day mortality in group A was 3.0% (n=2/67).
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
OUTCOMES OF FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATED WITH OXALIPLATIN-BASED PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE COLORECTAL PERITONEAL METASTASES IN A MULTICENTER, SINGLE-ARM, PHASE II TRIAL (Room S504) - May 11, 2023 - Abstract #SSAT2023SSAT_261;
Antitumor activity of bidirectional therapy is promising. However, randomized trials are needed to investigate the efficacy of PIPAC-OX treatment for unresectable, isolated colorectal peritoneal metastases.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
WHAT PREDICTS COMPLETE RESPONSE TO TNT IN LOCALLY ADVANCED RECTAL CANCER? (Room S504) - May 11, 2023 - Abstract #SSAT2023SSAT_164;
In this cohort of locally advanced rectal cancer patients, TNT achieved 36.9% CR.Absence of EMVI was the only independent predictor of CR at the time of diagnosis. Following TNT,endoscopy is a better predictor of CR than MRI.
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date: IMAGINE: Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (clinicaltrials.gov) - May 11, 2023
P2, N=21, Active, not recruiting, Sponsor: University Hospital, Essen
Following TNT,endoscopy is a better predictor of CR than MRI. Trial primary completion date: Apr 2023 --> Mar 2024
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Metastases: AtezoTRIBE: FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - May 11, 2023
P2, N=201, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial primary completion date: Apr 2023 --> Mar 2024 Trial completion date: Mar 2023 --> Aug 2023
- |||||||||| Jemperli (dostarlimab-gxly) / GSK
New P3 trial, Monotherapy: AZUR-2: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (clinicaltrials.gov) - May 11, 2023
P3, N=711, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation. (Pubmed Central) - May 10, 2023
All patients received gemcitabine plus cisplatin as the frontline therapy, and 53.2% received fluoropyrimidine plus oxaliplatin (FOLFOX) before ICI...This finding was not shown in patients with wild-type KRAS. Our analysis suggested that PD-L1 expression might be a useful biomarker for ICIs in BTC patients with KRAS mutation but not in those with wild-type KRAS.
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - May 10, 2023
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Our analysis suggested that PD-L1 expression might be a useful biomarker for ICIs in BTC patients with KRAS mutation but not in those with wild-type KRAS. Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Combination therapy, Metastases: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - May 10, 2023
P2, N=60, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Metastases: 😉No it's not #TumorBoardTuesday but I have a🧬molecular❓to ask you all😀 👉Patient with metastatic gastric cancer whose disease progressed on FOLFOX + nivo is found to have a🌟Gain of Function (Activating)🌟ERBB2 mutation ➡️No HER2⬆️by IHC🔬 🤔Would you try (inc. off label): (Twitter) - May 10, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Adverse events: #TumorBoardTuesday Ouch‼️ 63% Grade >=3 adverse events OK - no one is allowed to complain about FOLFIRINOX anymore😉 (Twitter) - May 9, 2023
- | Trial completion date, Trial primary completion date: Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer (clinicaltrials.gov) - May 9, 2023
P2, N=38, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024 Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
- | Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - May 9, 2023
P1, N=36, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Trial completion date, Trial primary completion date: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 9, 2023
P1, N=20, Recruiting, Sponsor: University of Louisville
Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - May 9, 2023
P1b/2, N=31, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Apr 2023 --> May 2024
- || nisevokitug (NIS793) / Novartis
Trial primary completion date: daNIS-3: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (clinicaltrials.gov) - May 8, 2023
P2, N=268, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2023 --> May 2024 Trial primary completion date: Sep 2024 --> May 2024
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
👀 PROSPECT trial evaluating standard neoadj Chemo RT vs FOLFOX 1st & selective use of ChemoRT to be in PLENARY at #ASCO23 Highly interested to see results given trend to start TnT with LCRT after OPRA. #CRCSM @OncBrothers (Twitter) - May 8, 2023
- ||| ST316 / Sapience Therap
New P1 trial: ST316-101: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (clinicaltrials.gov) - May 8, 2023
P1, N=156, Not yet recruiting, Sponsor: Sapience Therapeutics
- || Braftovi (encorafenib) / Pfizer
Enrollment closed, Metastases: NAUTICALCRC: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (clinicaltrials.gov) - May 8, 2023
P2, N=103, Active, not recruiting, Sponsor: Pierre Fabre Medicament
Trial primary completion date: Sep 2024 --> May 2024 Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Surgery, Metastases: Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment. (Pubmed Central) - May 7, 2023
CS after FFX contributes to the long-term survival of patients with LAPC. The CS score could be an indicator for transition to CS.
- | Trial primary completion date: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - May 6, 2023
P3, N=140, Not yet recruiting, Sponsor: University of Roma La Sapienza
The CS score could be an indicator for transition to CS. Trial primary completion date: Sep 2023 --> Sep 2024
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial initiation date, Combination therapy, Metastases: NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) - May 6, 2023
P2, N=171, Recruiting, Sponsor: NuCana plc
Trial primary completion date: Sep 2023 --> Sep 2024 Initiation date: Jan 2023 --> Apr 2023
- | Trial completion date, Trial primary completion date, Metastases: FOLFOXIRI With or Without Intensification for Rectal Cancer (clinicaltrials.gov) - May 6, 2023
P2, N=72, Recruiting, Sponsor: CCTU
Initiation date: Jan 2023 --> Apr 2023 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2024
- | Fruzaqla (fruquintinib) / Takeda
New P2 trial, Metastases: Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2023
P2, N=42, Not yet recruiting, Sponsor: Hunan Cancer Hospital
- | Avastin (bevacizumab) / Roche
New P2 trial: Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2023
P2, N=155, Not yet recruiting, Sponsor: University Health Network, Toronto
- |||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, drebuxelimab (AK119) / Akesobio
New P1/2 trial, Combination therapy, Metastases: Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients (clinicaltrials.gov) - May 6, 2023
P1/2, N=72, Not yet recruiting, Sponsor: Akeso
- | Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2023
P1, N=13, Active, not recruiting, Sponsor: Ning Jin
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- ||| Jemperli (dostarlimab-gxly) / GSK
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: CITRINO: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2023
P1, N=111, Completed, Sponsor: Tesaro, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Jun 2022
- XT-0528 / Boston Pharma, Xenter
Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_656;
P1
XT-0528 is a high-affinity RORgT inverse agonist with a demonstrated reduction in the key inflammatory cytokine IL-17 and a very good safety profile that is a promising agent for pancreatic cancer. Translational work demonstrates increased RORgT expression in human pancreatic cancer and RORgT inhibition led to tumor regression within a human xenograft tumor model.
- capecitabine / Generic mfg.
Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_649;
Translational work demonstrates increased RORgT expression in human pancreatic cancer and RORgT inhibition led to tumor regression within a human xenograft tumor model. Two hundred and eighty patients (23%) required further consolidation chemotherapy (commonly CAPOX or modified FOLFIRINOX) post Cape
- Progression-free survival with maintenance therapy with fluoropyrimidine in patients with advanced gastric and gastroesophageal junction cancer in a third level hospital in Mexico City (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_642;
The most frequently used first-line chemotherapy scheme was FOLFOX in 36%, followed by XELOX in 34% and FLOT in 18%... Maintenance therapy following induction fluoropyripimidine and platinum-based therapy is associated with long progression-free survival and improved toxicity profile.
- 5-fluorouracil / Generic mfg.
Perioperative chemotherapy for operable gastro-esophageal or gastric cancer: Anthracycline triplets versus FLOT (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_636;
No statistically significant difference was seen in pCR rates. Patients treated with FLOT did complete the full neoadjuvant chemotherapy regimen significantly more often and had more R0 resections.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_619;
MRI-guided total neoadjuvant treatment with a simultaneous integrated boost resulted in a high clinical and pathological complete remission of 68%, within this pilot study. This may be an emerging strategy to improve local control and organ preservation in the future.
- Inflammatory status as a predictor of resectability in borderline resectable pancreatic cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_617;
These markers are simple and accessible in our clinical practice, and may help to predict the response to treatments. Prospective studies are imperative to validate key tool in the decision-making of therapeutic strategies in the future.
- 5-fluorouracil / Generic mfg., docetaxel / Generic mfg.
Docetaxel-based perioperative chemotherapy in gastric and gastroesophageal (GEJ) adenocarcinomas (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_616;
The patients in both the groups are currently under follow up to capture the recurrence patterns, overall and relapse free survival duration. Limited by its size and retrospective nature, our audit points towards the need for a prospective well conducted study to compare these two regimens.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Safety and efficacy of short cetuximab infusion for patients with metastatic colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_606;
This led to shorter visit and chair time during the covid19 pandemic. This has the potential of saving time on chemotherapy chair, and associated healthcare costs.
- 5-fluorouracil / Generic mfg.
Outcomes of phosphorus-32 microparticle intratumoural implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_598;
EUS-guided 32 P-microparticles implantation to deliver 100Gy to target tumour appears safe in mPDAC patients receiving chemotherapy, with encouraging outcomes including 100% LDCR at 3 months post-implantation. This retrospective analysis highlights the potential clinical benefits, particularly of local tumour control and overall survival, in a metastatic cohort in whom outcomes are often poor.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_587;
This retrospective analysis highlights the potential clinical benefits, particularly of local tumour control and overall survival, in a metastatic cohort in whom outcomes are often poor. Results of this prospective observational study suggests that aflibercept plus FOLFIRI administered in mCRC patients who progressed during or after an oxaliplatin-based regimen retains its activity regardless of tumor sideness, KRAS status and metastatic site, and shows a manageable safety profilein daily clinical practice.
- Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_583;
Dose intensity of m-FOLFIRINOX was as follows: 65% for oxaliplatin, 68% for irinotecan, 18% for bolus 5-fluorouracil (5-FU) and 68% for infusional 5-FU... As demonstrated by a retrospective analysis of 128 patients in a single centre in WA, modified FOLFIRINOX is an effective second-line therapy for the treatment of locally advanced and metastatic pancreatic cancer who have failed first-line treatment with gemcitabine and nab-paclitaxel.
- 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Neoadjuvant chemotherapy of the mFOLFIRINOX in the treatment of resectable pancreatic cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_581;
mFOLFIRINOX/GemCap appeared to be an effective perioperative treatment for resectable pancreatic cancer. The results of this approach on survival will be forthcoming.
- 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_578;
Between 2010 and 2022 102 patients were included in the analysis... GemNab appeared to be more effective than gemcitabine monotherapy in patients with advanced pancreatic cancer as a second-line treatment after progression on mFOLFIRINOX and should be considered as a standard of care.